Login to Your Account

Ablynx, Eddingpharm Ink Chinese Pact on RANKL Inhibitor

By Cormac Sheridan
Staff Writer

Friday, October 18, 2013

Ablynx NV continues to crank out deals, its latest being a regional accord with Chinese specialty pharma firm Eddingpharm Co. Ltd. to develop and commercialize its anti-RANKL nanobody ALX-0141, for which it is receiving 2 million (US$2.7 million) up front, plus commercial milestones and tiered double-digit royalty payments.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription